Compare MPLX LP (MPLX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs Vertex Pharmaceuticals Incorporated — how do they compare? MPLX LP trades at $56.64 (market cap $57.97B), while Vertex Pharmaceuticals Incorporated trades at $478.12 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.1× MPLX LP's market cap, and MPLX LP pays a 7.54% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| MPLX | VRTX | |
|---|---|---|
Market Cap | $57.97B | $121.95B |
Sector | Technology | Health |
52-Week High | $59.17 | $529.59 |
52-Week Low | $47.80 | $366.54 |
Enterprise Value | $82.60B | $116.69B |
Dividend Yield | 7.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPLX trades at $57.13, showing modest daily gains of 0.12%. The stock maintains a bullish technical outlook with strong moving average signals, while fundamentals reveal robust profitability with 41.24% net margins and consistent earnings beats in recent quarters. Recent news highlights the company's resilient midstream business model and attractive dividend yield, with analyst consensus strongly favoring the stock.
Outlook remains positive given the 71% buy rating consensus and $60 price target representing 5% upside. Key risks include energy market volatility and the Q1 2026 earnings miss, but the company's fee-based contracts and Permian Basin exposure provide stability. The sustainable dividend and strong cash flow generation support long-term value for income-focused investors.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
